Maxburg has acquired a majority stake in MLase to expand its product portfolio and drive growth in the MedTech sector.
Information on the Target
MLase, founded in December 2007, specializes in the development and production of cutting-edge laser and light systems. The company’s products play a crucial role in a wide range of OEM systems utilized in medical fields such as refractive eye surgery, angiopathy, and glaucoma treatment. Additionally, their technology finds applications in various industrial sectors, showcasing versatility and innovation.
In close collaboration with a distinguished array of leading MedTech OEMs, MLase has consistently brought innovative solutions to market. The company's highly specialized team combines years of experience with the latest advancements in medicine, physics, optics, and electrical engineering to create top-quality products.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The medical technology industry in Germany is renowned for its innovation and quality, with a significant global market share. As one of the leading countries in healthcare technologies, Germany benefits from a
Similar Deals
Maxburg
invested in
MLase
in 2023
in a Buyout deal